Professor Bruce Robinson and Associate Professor Roderick Clifton-Bligh (Northern Clinical School, Kolling Institute) and their team have conducted several successful Pharamceutical Company sponsored clinical trials into the treatment of Medullary and Differentiated thyroid cancers which are metastatic, progressing and do not respond to standard treatment.
In 2006 the team began trialling Vandetanib, a drug used to treat patients with medullary thyroid cancer, a rare malignancy stemming from parafollicular C cells which produce calcitonin in the thyroid gland.
Vandetanib was deemed as an effective means to treat Medullary thyroid cancer and was consequently made available through prescription although not on the PBS.
In 2009 the team began studies using Lenvatinib to treat Medullary and Differentiated Thyroid Cancers resulting in Lenvatinib being made available to patients with Differentiated Thyroid cancer on the PBS.
The team is currently working on a number of other Clinical trials, including:
- The ongoing study of Cabozantinib for patients with Medullary Thyroid Cancer
- Their first ever phase one trial for a new medication, Loxo 292 in Medullary Thyroid Cancer
- An important study measuring the best starting dosage of Lenvatinib in Differentiated Thyroid Cancer.
The centre and its team of surgeons, researchers and endocrinologists are renowned for their work towards the treatment of thyroid diseases and receive a high volume of referrals as a result.
A/Prof Helen Wheeler
Medical Oncologist, special interest in neuro-oncology and clinical trials
“Adrenal cancer is an extremely rare cancer with limited treatment options and poor survival rates. We are working on a new drug therapy which directly kills the cancer cells, stops the cancer spreading and reduces the risk of damage to other organs, including the liver.”
Professor Stan Sidhu
Professor of Surgery at the Northern Clinical School and Kolling Institute of Medical Research
CLINICAL TRIAL: PARTICIPANTS WITH ADVANCED CANCER, NO CURATIVE TREATMENT OPTIONS
Prof Stan Sidhu (Professor of Surgery, Head of the University of Sydney Endocrine Surgical Unit) and his team have conducted a clinical trial; A study of EnGeneIC Dream Vectors (EDV’s) packaged with the chemotherapy PNU-159682, given simultaneously as non-targeted EDVs carrying an immune enhancer called EDVs40-mer, in participants with advanced cancer who have no curative treatment options.
Trail ID: ACTRN12617000037303